PMV Pharmaceuticals (PMVP) awards CEO 744,960 employee stock options

Rhea-AI Filing Summary

PMV Pharmaceuticals, Inc. granted President and CEO David Henry Mack an employee stock option covering 744,960 shares of common stock. The award was reported as an acquisition of derivative securities at a stated price of 0.0000 per share. These options vest in 48 equal monthly installments beginning on April 5, 2026, providing long-term, time-based equity compensation tied to his continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mack David Henry

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	744,960	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 744,960 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mack David Henry

(Last) (First) (Middle)

C/O PMV PHARMACEUTICALS, INC.

400 ALEXANDER PARK DRIVE, SUITE 301

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PMV Pharmaceuticals, Inc. [ PMVP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.53	03/05/2026		A		744,960		(1)	03/05/2036	Common Stock	744,960	$0	744,960	D

Explanation of Responses:

1. Shares subject to the option vest in 48 equal monthly installments beginning on April 5, 2026.

	/s/ Robert Ticktin, by power of attorney	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PMV Pharmaceuticals (PMVP) report for David Henry Mack?

PMV Pharmaceuticals granted President and CEO David Henry Mack an employee stock option for 744,960 shares. The award is classified as an acquisition of derivative securities, providing equity-based compensation that aligns his interests with shareholders through future potential ownership in the company.

How many PMV Pharmaceuticals shares are covered by David Henry Mack’s new option grant?

The new employee stock option covers 744,960 shares of PMV Pharmaceuticals common stock. This large grant represents a significant equity incentive intended to reward long-term service, with vesting spread over multiple years rather than all at once.

When do David Henry Mack’s PMV Pharmaceuticals options begin vesting and over what schedule?

The options begin vesting on April 5, 2026 and vest in 48 equal monthly installments. This four-year vesting structure encourages long-term alignment, as Mack must remain in service over time to fully realize the grant’s potential benefits.

What is the transaction code and direction for David Henry Mack’s PMVP option grant?

The transaction is coded “A” for a grant, award, or other acquisition and marked as an acquire direction. This means the options were awarded as compensation, rather than purchased or sold in an open-market or cash transaction.

Is David Henry Mack’s ownership in PMV Pharmaceuticals direct or indirect for this option grant?

The ownership for this option grant is reported as direct. That indicates the options are held in his own name, rather than through a trust, partnership, or other indirect entity structure associated with the reporting person.